AZD9977 clinical trials
Also written AZD9977.
How each study uses AZD9977 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the AZD9977 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
16 studies that test it; most in 2015 (3)
| Year | Studies |
|---|---|
| 2015 | 3 |
| 2018 | 3 |
| 2019 | 2 |
| 2020 | 2 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 15 · Other 1
AstraZeneca (15) · Klinikum Nürnberg (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses AZD9977 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 16
- A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)RecruitingPhase 3AstraZenecaNCT07624305Written as Balcinrenone/dapagliflozin
- Study of the Effect of Haemodialysis on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone/DapagliflozinCompletedPhase 1AstraZenecaNCT07754331Written as Balcinrenone/dapagliflozin
- A Study to Investigate the Mechanistic Effects of Dapagliflozin Alone or in Combination With Balcinrenone, Compared to Balcinrenone and Placebo on Body Fluid and Electrolyte Handling and Energy Metabolism in Participants Over 50 Years of Age With Chronic Kidney Disease.CompletedPhase 2Klinikum NürnbergNCT05884866Written as Balcinrenone 50mg Capsule
- A Study to Investigate the Effect of Food on Balcinrenone/Dapagliflozin Pharmacokinetics in Fed and Fasted State and Pharmacokinetics of Balcinrenone When Dosed With a P-gp Inhibitor in Healthy Participants.CompletedPhase 1AstraZenecaNCT06979388Written as balcinrenone/ dapagliflozin
- A Phase I PK Study of Balcinrenone/Dapagliflozin in Healthy Chinese ParticipantsCompletedPhase 1AstraZenecaNCT06651021Written as balcinrenone/dapagliflozin
- Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of BalcinrenoneCompletedPhase 1AstraZenecaNCT06388616Written as Balcinrenone
- Study to Assess the Pharmacokinetics and Safety of AZD9977 in Participants With Renal ImpairmentCompletedPhase 1AstraZenecaNCT04469907Written as AZD9977
- Absolute Bioavailability and ADME Study of [14C]AZD9977 in Healthy Male SubjectsCompletedPhase 1AstraZenecaNCT04686591Written as AZD9977 capsule 50 mg
- Study in HFpEF Patients to Compare the Effect of AZD9977 and Spironolactone on Serum PotassiumTerminatedPhase 1AstraZenecaNCT03682497Written as AZD9977
- A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 in Japanese Healthy Participants With Single and Multiple Ascending Dose AdministrationCompletedPhase 1AstraZenecaNCT03801967Written as AZD9977
- A Phase 1 Study to Assess the Pharmacokinetics of AZD9977 Administered Alone and in Combination With Itraconazole in Healthy VolunteersCompletedPhase 1AstraZenecaNCT03843060Written as AZD9977
- Multiple-ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 in Healthy Male SubjectsCompletedPhase 1AstraZenecaNCT03435276Written as AZD9977
- A Single Oral Dose Study to Evaluate Four Different Formulations of AZD9977 and the Effect of Food in Healthy Male SubjectsCompletedPhase 1AstraZenecaNCT03450759Written as AZD9977 Oral suspension (reference)
- A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 After Single Ascending Doses to Healthy MalesCompletedPhase 1AstraZenecaNCT02484729Written as AZD9977, oral suspension
- A Study to Assess the Pharmacodynamic Effect of Single Doses of AZD9977 in Healthy Male SubjectsCompletedPhase 1AstraZenecaNCT02532998Written as AZD9977 oral suspension
- A Study to Compare the Pharmacokinetics of Different Formulations of AZD9977 and the Influence of Food in Healthy Male SubjectsWithdrawnPhase 1AstraZenecaNCT02560363Written as AZD9977 immediate release (IR) oral suspension